Quarterly report pursuant to Section 13 or 15(d)

Commitments and Contingencies (Details)

v3.23.3
Commitments and Contingencies (Details)
1 Months Ended 3 Months Ended 9 Months Ended 12 Months Ended 40 Months Ended 64 Months Ended
Jul. 31, 2019
USD ($)
Sep. 30, 2018
USD ($)
milestone
therapy
Mar. 31, 2020
USD ($)
milestone
Sep. 30, 2023
USD ($)
Dec. 31, 2018
unit
$ / shares
Dec. 31, 2021
USD ($)
Dec. 31, 2023
USD ($)
Aug. 14, 2023
USD ($)
Jun. 22, 2021
USD ($)
Jun. 09, 2021
USD ($)
May 28, 2021
USD ($)
Mar. 25, 2021
USD ($)
Feb. 03, 2020
USD ($)
Operating Leased Assets [Line Items]                          
Payment received $ 2,000,000                        
Period after public launch to terminate agreement 3 years                        
Percentage of net present value of royalty payments 75.00%                        
Apollo AP43 Limited | Maximum                          
Operating Leased Assets [Line Items]                          
Estimate of possible loss               $ 837,522          
Apollo AP43 Limited | Minimum                          
Operating Leased Assets [Line Items]                          
Estimate of possible loss               $ 0          
Aevi                          
Operating Leased Assets [Line Items]                          
Milestone payment       $ 0                  
Aevi                          
Operating Leased Assets [Line Items]                          
Number of milestones | milestone     2                    
Contingent consideration     $ 6,500,000                    
Ichorion Therapeutics, Inc                          
Operating Leased Assets [Line Items]                          
Number of milestones | milestone   3                      
Contingent consideration   $ 15,000,000.0                      
Milestone payment       0                  
Milestone One | Aevi                          
Operating Leased Assets [Line Items]                          
Contingent consideration     $ 2,000,000                    
Milestone One | Ichorion Therapeutics, Inc                          
Operating Leased Assets [Line Items]                          
Milestone payment           $ 6,000,000              
Milestone Two | Aevi                          
Operating Leased Assets [Line Items]                          
Contingent consideration                         $ 4,500,000
Milestone Two | Ichorion Therapeutics, Inc | Forecast                          
Operating Leased Assets [Line Items]                          
Milestone payment             $ 5,000,000            
Milestone Three | Ichorion Therapeutics, Inc                          
Operating Leased Assets [Line Items]                          
Milestone payment       0                  
Milestone Three | Ichorion Therapeutics, Inc | Forecast                          
Operating Leased Assets [Line Items]                          
Milestone payment             $ 4,000,000            
Kyowa Kirin Co., Ltd. (KKC) | AVTX-002 KKC License Agreement                          
Operating Leased Assets [Line Items]                          
Upfront license fee                       $ 10,000,000  
Percent of payments received from sublicensing                       30.00%  
Research and development expense       0                  
Cumulative expense recognized to date       0                  
Kyowa Kirin Co., Ltd. (KKC) | AVTX-002 KKC License Agreement | Milestone One                          
Operating Leased Assets [Line Items]                          
Maximum aggregate milestone payment                       $ 112,500,000  
Kyowa Kirin Co., Ltd. (KKC) | AVTX-002 KKC License Agreement | Milestone Two                          
Operating Leased Assets [Line Items]                          
Maximum aggregate milestone payment                       $ 75,000,000  
Astellas Pharma, Inc. (Astellas) | AVTX-006 Astellas License Agreement                          
Operating Leased Assets [Line Items]                          
Upfront license fee       500,000                  
Maximum aggregate milestone payment       5,500,000                  
Research and development expense       0                  
Cumulative expense recognized to date       500,000                  
Sanford Burnham Prebys Medical Discovery Institute | AVTX-008 Sanford Burnham Prebys License Agreement                          
Operating Leased Assets [Line Items]                          
Upfront license fee                 $ 400,000        
Research and development expense       0                  
Cumulative expense recognized to date       0                  
Patent costs                 500,000        
Sanford Burnham Prebys Medical Discovery Institute | AVTX-008 Sanford Burnham Prebys License Agreement | Milestone One                          
Operating Leased Assets [Line Items]                          
Maximum aggregate milestone payment                 24,200,000        
Sanford Burnham Prebys Medical Discovery Institute | AVTX-008 Sanford Burnham Prebys License Agreement | Milestone Two                          
Operating Leased Assets [Line Items]                          
Maximum aggregate milestone payment                 $ 50,000,000        
TRIS Pharma | Karbinal Agreement                          
Operating Leased Assets [Line Items]                          
Minimum quantity required | unit         70,000                
Make whole payment per unit (in dollars per share) | $ / shares         $ 30                
AVTX-301 Out-License | Alto                          
Operating Leased Assets [Line Items]                          
Maximum proceeds from milestones                     $ 18,600,000    
Revenue recognized from milestones to date       0                  
AVTX-406 License Assignment | ES                          
Operating Leased Assets [Line Items]                          
Revenue recognized from milestones to date       $ 0                  
AVTX-406 License Assignment | ES | Milestone One                          
Operating Leased Assets [Line Items]                          
Maximum proceeds from milestones                   $ 6,000,000      
AVTX-406 License Assignment | ES | Milestone Two                          
Operating Leased Assets [Line Items]                          
Maximum proceeds from milestones                   $ 20,000,000      
AVTX-801, AVTX-802, And AVTX-803 | Ichorion Therapeutics, Inc                          
Operating Leased Assets [Line Items]                          
Number of preclinical therapies | therapy   3                      
AVTX-913 | Ichorion Therapeutics, Inc                          
Operating Leased Assets [Line Items]                          
Number of preclinical therapies | therapy   1